Abstract
Introduction

Apolipoprotein A-I (ApoA-I), the major component of high-density lipoproteins (HDL), is known to play a central role in cholesterol efflux from cells and transport to the liver [1], a crucial process to prevent cellular lipid overload as well as atherosclerosis.
Epidemiological studies have demonstrated that plasma levels of HDL, and their major constituent ApoA-I, are inversely correlated with the risk of atherosclerosis [2] . Nevertheless, the molecular mechanism of the atheroprotective action of ApoA-I, as well as HDL biogenesis, is not fully understood. ApoA-I may act as an extracellular receptor of cellular cholesterol and phospholipids. [3] [4] [5] , that mediates cholesterol efflux to ApoA-I. ApoA-I is also known to internalize to the endosomes, an intracellular reservoir of cholesterol, to bind lipids and to be resecreted to the medium as HDL [6] . Despite intense research activity suggesting a direct association between ApoA-I and ABCA1 [7] , whether or not ABCA1 is to be considered as an ApoA-I receptor is still ambiguous. ApoA-I association to cell surface might not involve direct binding to ABCA1; rather, ABCA1 would induce modifications of lipid distribution at the membrane facilitating ApoA-I docking [3] .
ApoA-I lipidation to form nascent HDL particles is a process that involves ATP-binding cassette transporter A1 (ABCA1)
Despite its protective role against hypercholesterolemia and cardiovascular diseases, ApoA-I is associated to systemic amyloidoses when specific mutations occur in the 243-residue sequence of ApoA-I. Amyloidoses, conformational diseases related to protein misfolding, have been associated to over 40 different peptides and proteins identified so far [8] . Mutations and/or environmental conditions able to destabilize the protein native conformation kinetically favour aggregate nucleation [9] leading to fibrils that accumulate in amyloid deposits in tissues and organs [8] .
Sixteen variants of ApoA-I are responsible for systemic amyloidoses characterized by aggregate deposition in peripheral organs, such as heart, liver or kidneys [1, 10, 11] . Amyloid fibrils isolated ex vivo were found to be mainly constituted by N-terminal fragments of ApoA-I, 90-100 residue long, released by a still unidentified protease. In particular, the fragment corresponding to sequence was found to be the main constituent of cardiac fibrils extracted from patients harbouring variant L174S ApoA-I [10] and affected by a severe systemic amyloidosis predominantly involving the heart. The 93-residue fibrillogenic domain of ApoA-I, extracted from amyloid deposits of a patient who underwent a heart transplant for end-stage heart failure, was found to be a natively unfolded protein in water at neutral pH [12] . Acidic conditions (pH 4) were able to switch on a complex fibrillogenic pathway, consisting of extensive structural rearrangements of the polypeptide, that shifts from a random coil structure to an unstable helical conformation, and then aggregates into a ␤-sheet based polymeric structure [12] .
We produced a recombinant version of ApoA-I 1-93 fragment, denoted as ApoA-I, as a pure and stable product, following a strategy aimed at protecting the recombinant polypeptide from intracellular degradation [13] . Conformational analyses revealed that recombinant ApoA-I, as the native polypeptide, undergoes conformational transitions and fibrillogenesis, leading to the formation of typical amyloid fibrils on a time scale comparable with that of the natural polypeptide [13] .
Nothing is known about the mechanism leading to the release of the fibrillogenic polypeptide from a full-length amyloidogenic variant of ApoA-I, or [14] . Recently, we suggested that lipids have a key role in ApoA-I aggregation [15] , as cholesterol, a natural ApoA-I ligand, was found to induce and stabilize helical conformers, slowing down the aggregation process. Moreover, zwitterionic, positively and negatively charged liposomes were found to affect ApoA-I conformation by inducing the formation of helical species [15] 
Materials and methods
Proteins and reagents
Protein degradation analyses
To inhibit proteasome activity, cells were pre-treated for 4 hrs at 37ЊC with 2.5 M Z-Leu-Leu-Leu-al (MG132), or with 10 M N-Ac-Leu-Leunorleucinal (ALLN). Cells were then incubated with the fluorescent protein for the indicated times. Intralysosomal catabolism was inhibited by treating cells with 20 mM ammonium chloride or 100 M chloroquine. As a control, cells were incubated under the same conditions but in the absence of the inhibitors.
Results [1-93]ApoA-I binding to cardiomyoblasts
The ability of Fig. 2A , after 2 hrs incubation the polypeptide (green) mostly co-localizes with ␤-catenin (red), whereas after 6 hrs the polypeptide fluorescent signal was found to be mostly intracellular (Fig. 2B) . Hence, the polypeptide binds to the membrane first and then is internalized in target cells. Similar results were obtained with labelled ApoA-I (Fig. 2C and D) Fig. 3D . Similar results were obtained with rhodamine-ApoA-I (Fig. 3E ), in agreement with recent reports showing that the majority of cellassociated ApoA-I does not co-localize with ABCA1 [25] . Fig. 4C, strong (Fig. 4D) .
Immunostaining was specific as no signals were detected in the absence of primary antibody (data not shown).
Internalization pathway of [1-93]ApoA-I
To learn about the mechanism of [1-93]ApoA-I uptake in cardiomyoblasts, we analysed different routes of endocytosis. First, the involvement of chlathrin-coated pits was evaluated using Rab5 as a marker, as this protein regulates vesicular transport from the plasma membrane to the endosomes. We transiently expressed Rab5 fused to the RFP in H9c2 cells. Twenty-four hours after transfection, cells were incubated with the FITC protein under test
Fig. 2 Endocytosis of [1-93]ApoA-I and full-length ApoA-I in H9c2 cells. Cells were grown on cover slips, incubated 2 hrs (A) or 6 hrs (B) with 3 M FITC-[1-93]ApoA-I (green) and immunofluorescently stained for ␤-catenin (red). (C) and (D), cells incubated 2 or 6 hrs, respectively, with 1 M FITC-ApoA-I (green) and immunostained for ␤-catenin (red). Nuclei were stained with Hoechst (blue). Cells were analysed by epifluorescence microscopy. for 6 hrs at 37ЊC, to allow internalization. As indicated in Fig. 4A, a significant, albeit partial, co-localization of internalized [1-93]ApoA-I (green) with RFP-Rab5 (red) was observed, indicating that a fraction of the internalized polypeptide is associated to early endosomes. Similar results were obtained when ApoA-I was tested (Fig. 4B), in line with recent findings [4, 5]. Additional experiments were performed with labelled transferrin (FITC-Tf), as a marker of the endocytic pathway. For both proteins we confirmed the results obtained with Rab5, because after 6 hrs incubation partial co-localization with FITC-Tf was observed (data not shown). To further confirm that both [1-93]ApoA-I and ApoA-I are internalized in H9c2 cells by chlatrin-mediated endocytosis, we used specific inhibitors of this internalization pathway, such as MDC and sucrose. Upon pre-incubation of H9c2 cells with either MDC or sucrose, we observed that the amount of internalized polypeptide, and that of the full-length protein, appeared to be reduced (data not shown). Hence, endocytosis of both proteins is slowed down, although not fully blocked, by inhibitors of chlatrinmediated endocytosis. This indicates either that in our experimental conditions the endocytic pathway still functions, albeit less efficiently, or that endocytosis of [1-93]ApoA-I and ApoA-I does not occur solely via chlathrin-coated pits. Experiments were then performed to test internalization by lipid rafts. To do so, FITC insulin was used as a marker. H9c2 cells were incubated with rhodamine-[1-93]ApoA-I in the presence of FITC insulin for 4 hrs at 37ЊC. As shown in
As it has been demonstrated that ApoA-I is also internalized by macropinocytosis [4] , we tested this internalization route for 
ApoA-I. H9c2 cells were incubated with rhodamine-[1-93]ApoA-I in the presence of FITC dextran, a macropinocytosis marker, for 4 hrs at 37ЊC. As shown in Fig. 4E, little co-localization was observed between [1-93]ApoA-I (red) and dextran (green). On the contrary, clear signals of co-localization were detected for
ApoA-I (Fig. 4F) .
According to recent reports, ApoA-I, once internalized, is recycled back to the cell surface [3] [4] [5] (Fig. 6B) , indicative of proteasome involvement in ApoA-I degradation.
Fig. 3 ABCA1 expression and co-localization with [1-93]ApoA-I and ApoA-I. (A) Western blot analysis with anti-ABCA1 antibodies of cell lysates prepared from HepG2 cells (25 g total proteins, lane 1) and from H9c2 cells (50 g, lane 2). Immunostaining for ABCA1 (green) of HepG2 cells (B) and H9c2 cells (C). Nuclei were stained with Hoechst (blue). (D) and (E), co-localization of [1-93]ApoA-I and ApoA-I with ABCA1. H9c2 cells were incubated for 2 hrs either with 3 M rhodamine-[1-93]ApoA-I (D), or with 1 M rhodamine-ApoA-I (E), and immunostained for ABCA1 (green). Nuclei were stained with Hoechst (blue). Cells were observed by confocal microscopy.
To test whether 
Analysis of the uptake of [1-93]ApoA-I fibrils in cardiomyoblasts and the effects on cell viability
As it is conceivable that the accumulation of the fibrillogenic polypeptide in the extracellular space leads to fibrils deposition, 
mg/ml). (E) and (F), macropinocytosis. Cells were incubated 4 hrs at 37ЊC either with 3 M rhodamine-[1-93]ApoA-I (E), or with 1 M rhodamine-ApoA-I (F), in the presence of FITC dextran (5 mg/ml). Nuclei were stained with Hoechst (blue).
[ (Fig. 7B) . This was confirmed by the absence of apoptotic nuclei in treated cells (Fig. 7B) .
To verify whether the fibrillar material is able to enter the cells, we produced fluorescent fibrils by incubating FITC-labelled ApoA-I under the conditions previously described. H9c2 cells were incubated for 6 hrs with fluorescent fibrils (insoluble species) and then treated with Hepes/NaCl buffer to remove polypeptide molecules specifically bound to the extracellular side of the plasma membrane. No fluorescent signals associated to ApoA-I fibrils were observed by epifluorescence microscopy analysis, demonstrating that no significant internalization of fibrils occurs in cardiomyoblasts (Fig. 7C) . [1, 10, 11] . The molecular mechanism responsible for ApoA-I associated amyloid diseases remains largely unknown. However, recent findings allowed us to raise the hypothesis that the mutations located in ApoA-I N-terminal region are amyloidogenic as they favour the proteolytic cleavage responsible for the release of the fibrillogenic polypeptide [26] .
As the heart is one of the targets of to HepG2 cells [29] . Our data are also reinforced by the finding that region 1-43 is involved in ApoA-I lipid binding [14] . As ABCA1 transporter plays a central role in ApoA-I membrane binding and lipidation [3] [4] [5] [25] . To explain these observations, a model was recently proposed [4, 30] [32] . The question of the physiological role of ApoA-I in lysosomes remains controversial. In fact, some authors demonstrated that ApoA-I reaches lysosomes to be degraded [3, 4] [10] . During the fibrillogenic process, a dynamic equilibrium between monomeric species and aggregated states has been proposed [36] . Here 
